3.2) By 2030, end preventable deaths of newborns and children under 5 years of age, with all countries aiming to reduce neonatal mortality to at least as low as 12 per 1,000 live births and under-5 mortality to at least as low as 25 per 1,000 live births
Created in 2000, Gavi, the Vaccine Alliance, is an international organization, bringing together public and private sectors, with the shared goal of creating equal access to new and underused vaccines for children living in the world’s poorest countries. To date, Gavi has immunized more than 500 million children and saved more than 7 million lives. Since beginning its relationship with Gavi in 2001, Pfizer has helped Gavi achieve its goals by increasing access to immunizations on an accelerated, affordable and sustainable basis. Pfizer has committed to supply up to 740 million doses of PCV13 through Gavi, to countries that carry the greatest burden of pneumococcal disease. In 2014, for Gavi eligible and Gavi Graduated countries, Pfizer lowered the per dose price of PCV13 in the single dose vial (SDV) presentation from $3.50 to $3.30 and committed to maintain this price through 2025. Additionally, if and when PCV13 in the four dose, multi-dose vial (MDV) presentation has been submitted to and approved by the European Medicine Agency and pre-qualified by the World Health Organization, Pfizer has committed to a per dose price of $3.10 for Gavi eligible and Gavi Graduated countries.
3.3) By 2030, end the epidemics of AIDS, tuberculosis, malaria and neglected tropical diseases and combat hepatitis, water-borne diseases and other communicable diseases
Trachoma is the world’s leading cause of infectious blindness. It is endemic in 51 countries and is responsible for the visual impairment of an estimated 2.2 million people, of whom 1.2 million are irreversibly blind. The poorest of the poor suffer most from trachoma, especially in areas that have limited access to water and sanitation. However, trachoma is treatable and preventable with a multifaceted approach known as the SAFE strategy. Recommended by the World Health Organization, the SAFE strategy is a comprehensive public health approach that combines treatment (Surgery and Antibiotics) with prevention (Facial-cleanliness and Environmental improvement). The International Trachoma Initiative (ITI), a global program Pfizer helped to establish, has been working since 1998 to eliminate blinding trachoma as a public health concern. Through the ITI, Pfizer has donated more than 450 million doses of the antibiotic Zithromax® (azithromycin), as a part of the “A” component of the SAFE strategy, to prevent and treat trachoma in support of the World Health Organization-led Global Alliance for the Elimination of Trachoma by the year 2020.
3.4) By 2030, reduce by one third premature mortality from non-communicable diseases through prevention and treatment and promote mental health and well-being
China produces more tobacco and has more smokers than any other country in the world. In recent years, Chinese officials have shown interest in regulating tobacco use, but more can be done to put sufficient policies and programs in place to curb smoking and protect non-smokers from secondhand smoke. In 2015, Pfizer Inc. granted nearly $850,000 to Georgia State University’s School of Public Health to partner with Chinese health officials to expand tobacco control efforts to major cities in China. The grant supports policies, media campaigns and programs to protect non-smokers from second-hand smoke, encourage smokers to quit and prevent women, children and young adults from starting smoking in China cities. It builds on tobacco control work conducted in China by a team of researchers from Georgia State University and Emory that was previously funded by the Bill & Melinda Gates Foundation. The program began in 2008 and has led to significant social norm changes and the development of extensive relationships with national and local public health leaders.
3.7) By 2030, ensure universal access to sexual and reproductive health-care services, including for family planning, information and education, and the integration of reproductive health into national strategies and programmes
A novel agreement with the Bill & Melinda Gates Foundation and the Children's Investment Fund Foundation is helping broaden access to Pfizer's long-acting contraceptive, Sayana® Press (medroxyprogesterone acetate), for women most in need in 69 of the world’s poorest countries.
Sayana® Press combines a long-acting, reversible contraceptive with an all-in-one pre-filled, single-use, non-reusable injection. Created with this target population of women in mind, Sayana® Press eliminates the need to prepare a needle and syringe, allowing the contraceptive to be administered by health workers at home or in other low-resource, non-clinic settings.
Through this agreement and the support of a public/private sector consortium including PATH, the United Kingdom's Department for International Development, the United Nations Population Fund, and the United States Agency for International Development, Sayana® Press is being sold for one U.S. dollar per dose to qualified purchasers, who are helping enable the poorest women in these countries to have access to the contraceptive at reduced or no cost.
Sayana® Press is not approved or available in the US.
 Family Planning 2020. Available at: http://www.familyplanning2020.org/articles/4458. Accessed: September 15, 2015.
3.8) Achieve universal health coverage, including financial risk protection, access to quality essential health-care services and access to safe, effective, quality and affordable essential medicines and vaccines for all
HelpAge International and Pfizer have worked together since 2012 to reduce the impact of non-communicable diseases (NCDs) among older people in Tanzania. During the first two years, the initiative focused on raising awareness among older people and health providers contributing to the Government of Tanzania's efforts to provide appropriate health services to older citizens. NCDs include a range of chronic conditions, including cancer, diabetes, cardiovascular disease and hypertension, as well as Alzheimer's and other dementias. They are commonly thought of as “diseases of affluence,” whereas, in reality, four-fifths of deaths from NCDs are in low- and middle-income countries and older people in developing countries are particularly at risk. Prevention through an active and healthy lifestyle can turn some of these debilitating diseases into manageable conditions.
The ongoing project focuses on developing health messaging through an intergenerational approach and includes the strengthening of community based initiatives such as active aging groups. These initiatives are aimed at promoting prevention and management of NCDs by practicing healthy lifestyles, while working with health providers at local and national levels to improve prevention, early diagnosis, follow-up and treatment of NCDs, as well as improving on data collection and analysis to inform appropriate policies. While the community-based activities are carried out in Morogoro, Kibaha and Songea districts, at the national level the project supports health advocacy including curriculum reform, increase access to essential NCD drugs and support to improve health information management with the Ministry of Health and Social Welfare.